The Total Return for CSPC Innovation Pharmaceutical (SZSE:300765) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are hard to find, but they can generate massive returns over long periods. To wit,

Simply Wall St01:27 ET

New Novus (300765.SZ): A total cost of 39.2313 million yuan to buy back 1.488,200 shares

On May 7, GLONGHUI (300765.SZ) announced that as of April 30, 2024, the company had repurchased 1.488,200 shares of the company's shares through a special stock repurchase securities account, accounting for 0.11% of the company's current total share capital. The highest transaction price was 34.99 yuan/share, the minimum transaction price was 18.68 yuan/share, and the total amount paid was 39.2313 million yuan (excluding transaction fees).

Gelonghui FinanceMay 7 04:36 ET

CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

It is hard to get excited after looking at CSPC Innovation Pharmaceutical's (SZSE:300765) recent performance, when its stock has declined 7.0% over the past month. However, a closer look at its soun

Simply Wall StApr 24 01:50 ET

New Novus (300765.SZ): Net profit of 79.0613 million yuan in the first quarter decreased by 38.86% year on year

On April 22, GLONGHUI (300765.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 524 million yuan, down 27.08% year on year; net profit attributable to shareholders of listed companies was 79.0613 million yuan, down 38.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 78.171,5 million yuan, down 56.44% year on year; basic earnings per share were 0.0676 yuan.

Gelonghui FinanceApr 22 09:07 ET

New Novus (300765.SZ) plans to transfer 10 shares and increase 2 shares to pay 3.2 yuan before interest deduction on April 25

New Novus (300765.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...

Zhitong FinanceApr 19 08:01 ET

New Novus (300765.SZ): Medication Clinical Trial Approval Notice for Obtaining Antibody Drug Conjugate (ADC) SYS6023

On March 20, GLONGHUI (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Biotech”), recently received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” on the antibody drug conjugate (ADC) SYS6023 and will conduct clinical trials in the near future. SYS6023 is a monoclonal antibody drug conjugate that binds to specific receptors on the surface of tumors, enters cells through endocytosis, releases toxins, and kills tumor cells. This product is classified as a therapeutic biological product category 1

Gelonghui FinanceMar 20 04:01 ET